What does this research mean for the field?

CPVT is a complex syndrome with variable expressivity whose management is evolving toward genotype-specific and mechanism-targeted therapies, such as flecainide, while reducing reliance on implantable cardioverter defibrillators. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

November 18, 2016Current Opinion in Cardiology

Catecholaminergic polymorphic ventricular tachycardia

View Full Paper

Ask AI

Bookmark

Population

Patients with Catecholaminergic polymorphic ventricular tachycardia (CPVT)

Design

Review

Authors

TRThomas M. RostonElectrophysiology FPFilip Van PetegemElectrophysiology SSShubhayan SanataniElectrophysiology

Discussion

Member takes

Implication

May warrant limiting ICDs in CPVT; leaves open prospective validation of flecainide and denervation.

Structured PICO

Population

Patients with Catecholaminergic polymorphic ventricular tachycardia (CPVT)

Intervention

Genotype-specific therapies, beta-blockers, implantable cardioverter defibrillators, flecainide, cardiac denervation, and gene therapy

This review highlights the evolving management of CPVT, emphasizing the growing role of flecainide and cardiac denervation over traditional reliance on ICDs.

Cite This Study

Roston et al. (2016) studied this question.

synapsesocial.com/papers/6a1e835120458ccdef55fc21 https://doi.org/10.1097/hco.0000000000000360

Topics

Ventricular arrhythmias Cardiac device therapy

View Full Paper

Ask AI

Bookmark

Catecholaminergic polymorphic ventricular tachycardia

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Topics

Catecholaminergic polymorphic ventricular tachycardia

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider